Advancements in Obesity Management: The Role of Transdermal Metformin Delivery via Microneedle Arrays

Abstract

Obesity, a multifaceted chronic disease characterized by excessive adiposity, poses a formidable and escalating global health crisis. Its intricate pathophysiology encompasses dysregulated energy balance, adipose tissue dysfunction, and chronic low-grade inflammation, collectively contributing to a wide spectrum of severe comorbidities including type 2 diabetes, cardiovascular diseases, certain cancers, and musculoskeletal disorders. While conventional management strategies, such as comprehensive lifestyle modifications, targeted pharmacological interventions, and various surgical procedures, have demonstrated demonstrable efficacy in achieving weight reduction and improving metabolic health, their limitations, including challenges with long-term adherence, potential adverse effects, and invasiveness, underscore the urgent need for innovative therapeutic modalities. This comprehensive report meticulously explores the complex etiology and pathophysiological mechanisms underlying obesity, critically evaluates the current landscape of therapeutic approaches, and delves into the profound potential of advanced drug delivery systems, particularly the utilization of microneedle (MN) arrays for targeted transdermal administration of therapeutic agents. Special emphasis is placed on the groundbreaking application of transdermal metformin delivery via MN arrays, examining its multifaceted role in promoting white adipose tissue (WAT) browning—a process converting energy-storing white adipocytes into energy-expending beige adipocytes—and its significant capacity to ameliorate systemic inflammation, thereby offering a novel, minimally invasive avenue for enhanced obesity management and metabolic amelioration.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction: The Global Scourge of Obesity and the Quest for Novel Therapies

Obesity is formally recognized as a chronic, relapsing, multifactorial disease defined by an abnormal or excessive fat accumulation that presents a risk to health. The World Health Organization (WHO) defines overweight as a body mass index (BMI) equal to or greater than 25 kg/m² and obesity as a BMI equal to or greater than 30 kg/m². This seemingly straightforward definition belies a profound complexity, as obesity is not merely a cosmetic concern but a profound metabolic disorder with pervasive systemic implications. The global prevalence of obesity has surged dramatically over the past few decades, evolving into an epidemic that transcends socioeconomic boundaries and poses an immense burden on healthcare systems worldwide. Projections indicate that by 2030, an estimated 1 billion adults will be living with obesity globally, underscoring the urgency for more effective, sustainable, and accessible treatment strategies.

The genesis of obesity is a complex interplay of genetic predispositions, epigenetic modifications, environmental influences, and behavioral patterns. It is fundamentally characterized by a chronic positive energy balance, where caloric intake consistently surpasses energy expenditure, leading to the relentless expansion of adipose tissue. This excess adiposity is not merely an inert energy storage depot; rather, it is a highly dynamic endocrine organ that, when dysfunctional, orchestrates a cascade of pathological processes, including systemic inflammation, insulin resistance, and dyslipidemia. These metabolic derangements are direct conduits to the myriad comorbidities associated with obesity, such as type 2 diabetes mellitus, hypertension, dyslipidemia, cardiovascular diseases (e.g., coronary artery disease, stroke), certain types of cancer (e.g., colorectal, breast, endometrial, kidney, liver), non-alcoholic fatty liver disease (NAFLD), sleep apnea, osteoarthritis, and psychological distress.

Despite the established efficacy of traditional interventions, their inherent limitations often impede long-term success. Lifestyle modifications, while foundational, frequently encounter challenges related to adherence and sustainability. Pharmacological agents, though effective for some, are often associated with systemic side effects and require chronic administration. Bariatric surgery, while offering profound and sustained weight loss, is an invasive procedure with inherent surgical risks and necessitates lifelong nutritional and medical follow-up. Consequently, there is an imperative to develop innovative, less invasive, and more targeted therapeutic approaches that can address the multifaceted nature of obesity and improve patient outcomes.

Recent advancements in drug delivery technologies represent a promising frontier in this regard. Among these, transdermal drug delivery systems, particularly those employing microneedle (MN) arrays, have garnered significant attention. These systems offer a non-invasive, patient-friendly route for drug administration, bypassing gastrointestinal degradation and first-pass hepatic metabolism, while potentially enabling targeted delivery to specific tissues. This report will extensively explore the application of MN technology for the transdermal delivery of metformin, an established antidiabetic agent, repositioned for its emerging role in promoting white adipose tissue (WAT) browning and its anti-inflammatory properties, thereby presenting a novel paradigm for obesity management.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Pathophysiology of Obesity: A Comprehensive Molecular and Cellular Perspective

Obesity is a highly complex metabolic disorder, not simply a matter of willpower or dietary indiscretion. Its pathophysiology involves an intricate web of genetic, epigenetic, environmental, and behavioral factors that collectively disrupt the delicate balance between energy intake and energy expenditure. Understanding these underlying mechanisms is crucial for developing effective and targeted therapeutic strategies.

2.1. Dysregulation of Energy Balance and Adipose Tissue Expansion

The fundamental premise of obesity is a sustained positive energy balance. When caloric intake consistently exceeds energy expenditure, the surplus energy is stored primarily as triglycerides within adipocytes. This leads to two distinct processes within adipose tissue: hypertrophy (increase in adipocyte size) and hyperplasia (increase in adipocyte number). Initially, adipose tissue expands healthily, accommodating excess lipids. However, prolonged positive energy balance eventually overwhelms the storage capacity, leading to adipocyte dysfunction.

Adipose tissue is not merely a passive storage depot but an active endocrine organ that secretes a variety of hormones and cytokines, collectively known as adipokines. In a healthy state, adipokines like leptin and adiponectin play crucial roles in regulating appetite, energy expenditure, and insulin sensitivity. However, in obesity, the secretion profile of these adipokines becomes dysregulated. Leptin resistance, where the brain fails to respond to elevated leptin levels signaling satiety, contributes to continuous overeating. Adiponectin levels, which typically enhance insulin sensitivity and possess anti-inflammatory properties, are often reduced in obesity, further exacerbating metabolic dysfunction.

2.2. Adipose Tissue Types and Their Roles

Human adipose tissue exists in different forms, each with distinct functions:

• White Adipose Tissue (WAT): The predominant form, primarily responsible for energy storage in the form of triglycerides. WAT also secretes various adipokines. In obesity, WAT expands significantly, often becoming dysfunctional.
• Brown Adipose Tissue (BAT): Specialized for non-shivering thermogenesis, burning energy to produce heat rather than ATP. BAT is rich in mitochondria and expresses uncoupling protein 1 (UCP1), which dissipates the proton gradient across the inner mitochondrial membrane as heat. While historically thought to be prominent only in infants, functional BAT has been identified in adult humans, predominantly in supraclavicular and paravertebral regions.
• Beige/Brite Adipose Tissue: These are UCP1-expressing thermogenic adipocytes found within WAT depots. They arise from specific precursor cells or through transdifferentiation of white adipocytes in a process known as ‘browning’ or ‘beiging’ in response to certain stimuli (e.g., cold exposure, β3-adrenergic agonists, exercise, certain pharmacological agents). The induction of WAT browning is a highly attractive therapeutic strategy for obesity, as it increases energy expenditure by converting energy-storing cells into energy-burning cells.

2.3. Chronic Low-Grade Inflammation (Meta-inflammation)

A hallmark of obesity is the development of a chronic, low-grade inflammatory state, often termed ‘meta-inflammation.’ As WAT expands beyond its healthy capacity, adipocytes become hypertrophied and stressed. This stress triggers a localized inflammatory response, characterized by the infiltration of immune cells, particularly macrophages, into the adipose tissue. These M1-polarized macrophages secrete an array of pro-inflammatory cytokines, including:

• Tumor Necrosis Factor-alpha (TNF-α): Directly impairs insulin signaling by inhibiting tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1).
• Interleukin-6 (IL-6): Contributes to systemic inflammation and can impair insulin signaling in certain tissues.
• Monocyte Chemoattractant Protein-1 (MCP-1): Attracts more monocytes (precursors to macrophages) into the adipose tissue, perpetuating the inflammatory cycle.
• Interleukin-1 beta (IL-1β): Produced by inflammasomes, it contributes to insulin resistance and pancreatic beta-cell dysfunction.

These pro-inflammatory adipokines enter the systemic circulation, creating a chronic inflammatory milieu that affects distant organs. This systemic inflammation is a critical driver of insulin resistance in peripheral tissues (muscle, liver) and contributes significantly to the development of type 2 diabetes, cardiovascular disease, and NAFLD. It also impairs the function of regulatory T cells, further tipping the immune balance towards inflammation.

2.4. Genetic, Epigenetic, and Environmental Factors

While energy imbalance is the proximal cause, a deeper understanding reveals multifaceted influences:

• Genetic Predisposition: Heritability estimates for BMI range from 40% to 70%. Over 100 genes have been associated with obesity risk, including genes involved in appetite regulation (e.g., FTO, MC4R), adipogenesis, and energy expenditure. However, genetics alone do not explain the rapid rise in obesity prevalence; they rather influence an individual’s susceptibility in an obesogenic environment.
• Epigenetic Modifications: These are heritable changes in gene expression that occur without altering the underlying DNA sequence. Environmental factors (diet, stress, toxins) can induce epigenetic changes (e.g., DNA methylation, histone modification) that influence energy metabolism and adipocyte development, potentially contributing to obesity risk across generations.
• Environmental Factors: The modern ‘obesogenic’ environment plays a critical role. This includes:
  • Dietary Composition: High intake of ultra-processed foods, refined carbohydrates, and saturated fats. The Western diet, characterized by high caloric density and low nutrient density, promotes rapid weight gain.
  • Sedentary Lifestyles: Reduced physical activity due to technological advancements and urbanization.
  • Sleep Deprivation: Chronic lack of sleep alters hormones regulating appetite (ghrelin, leptin) and impairs glucose metabolism.
  • Stress: Chronic stress can lead to increased cortisol levels, which promotes central fat accumulation and insulin resistance.
  • Gut Microbiome Dysbiosis: Alterations in the composition and function of the gut microbiota have been linked to energy harvest, inflammation, and metabolic dysfunction in obesity.
  • Endocrine Disrupting Chemicals (Obesity-gens): Certain chemicals in the environment may interfere with hormonal regulation of metabolism and promote adipogenesis.

In essence, obesity is a complex adaptive response of the body’s energy homeostasis system to a confluence of predisposing genetic factors and pervasive environmental challenges, culminating in chronic energy surplus, dysfunctional adipose tissue, and systemic meta-inflammation. Effective treatments must therefore address these multifaceted pathological pathways.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Current and Emerging Treatment Modalities: A Critical Appraisal

The management of obesity typically involves a stepped-care approach, progressing from least to most invasive interventions depending on the degree of obesity, presence of comorbidities, and individual patient circumstances. Despite significant advancements, achieving sustained weight loss and remission of comorbidities remains a substantial challenge for many individuals.

3.1. Lifestyle Modifications: The Foundational Pillar

Lifestyle interventions, encompassing dietary changes, increased physical activity, and behavioral therapy, form the cornerstone of obesity management. They are essential for all individuals with overweight or obesity, regardless of whether they receive pharmacological or surgical interventions.

3.1.1. Dietary Interventions

The primary goal of dietary interventions is to create a sustained caloric deficit. While numerous dietary approaches exist, the most effective ones are those that are sustainable and lead to a negative energy balance.

• Caloric Restriction: A reduction of 500-750 kcal/day from baseline typically leads to a weight loss of 0.5-1 kg/week. Diets often range from 1200-1800 kcal/day depending on individual needs. Long-term adherence is paramount, and strategies often focus on nutrient-dense foods.
• Macronutrient Manipulation:
  • Low-Fat Diets: Historically popular, these diets emphasize reducing dietary fat intake, which is calorically dense. Effectiveness varies, as many low-fat products compensate with high sugar content.
  • Low-Carbohydrate Diets (e.g., Ketogenic Diet): Restrict carbohydrate intake, inducing ketosis. While effective for initial rapid weight loss, their long-term sustainability and nutritional adequacy are subjects of ongoing debate. They may improve glycemic control.
  • Mediterranean Diet: Emphasizes fruits, vegetables, whole grains, legumes, nuts, seeds, olive oil, and moderate fish/poultry, with limited red meat and processed foods. It is more of a healthy eating pattern than a restrictive diet, promoting cardiovascular health and sustainable weight management.
  • High-Protein Diets: Increase satiety and help preserve lean muscle mass during weight loss, potentially beneficial for long-term maintenance.
• Meal Replacement Programs: Structured programs utilizing shakes or bars for some meals can provide controlled portions and calories, aiding initial weight loss, but transition to whole foods is crucial for sustainability.
• Behavioral Strategies: Encouraging mindful eating, portion control, food journaling, and reducing emotional eating are vital components that complement dietary changes.

Challenges: Despite initial success, long-term adherence to strict dietary regimens is notoriously difficult due to psychological factors, social pressures, metabolic adaptations (e.g., reduced resting energy expenditure, increased hunger hormones), and the pervasive availability of calorie-dense foods. Weight regain is a common phenomenon, often attributed to these compensatory physiological and psychological responses.

3.1.2. Increased Physical Activity

Regular physical activity contributes to weight loss by increasing energy expenditure and preserving lean body mass, which helps maintain resting metabolic rate. Beyond weight loss, exercise significantly improves insulin sensitivity, cardiovascular health, bone density, and mental well-being, irrespective of weight changes.

• Aerobic Exercise: Activities like brisk walking, jogging, cycling, or swimming, aiming for at least 150-300 minutes of moderate-intensity or 75-150 minutes of vigorous-intensity exercise per week. Higher durations (e.g., >250 minutes/week) are often required for significant weight loss and maintenance.
• Resistance Training: Building muscle mass is crucial for boosting metabolism and improving body composition. Two to three sessions per week targeting major muscle groups are recommended.
• Reducing Sedentary Behavior: Incorporating more movement throughout the day, beyond structured exercise, is also important.

Challenges: Similar to dietary changes, maintaining consistent physical activity levels can be challenging due to time constraints, lack of motivation, physical limitations, and environmental barriers.

3.1.3. Behavioral Therapy

Behavioral interventions are crucial for addressing the psychological and behavioral underpinnings of obesity. These often involve:

• Cognitive Behavioral Therapy (CBT): Helps individuals identify and modify unhealthy thought patterns and behaviors related to eating and physical activity.
• Motivational Interviewing: A client-centered approach to elicit and strengthen intrinsic motivation for change.
• Self-Monitoring: Tracking food intake, physical activity, and weight to increase awareness and accountability.
• Goal Setting and Problem Solving: Developing realistic goals and strategies to overcome barriers.
• Social Support: Engaging family, friends, or support groups to foster accountability and encouragement.

3.2. Pharmacological Interventions

Pharmacotherapy for obesity is typically considered for individuals with a BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with weight-related comorbidities, who have not achieved adequate weight loss through lifestyle interventions alone. These medications act through various mechanisms to reduce appetite, increase satiety, or decrease nutrient absorption.

• Semaglutide (Wegovy, Ozempic): A glucagon-like peptide-1 (GLP-1) receptor agonist administered via subcutaneous injection. GLP-1 is an incretin hormone that enhances glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying, and reduces appetite by acting on central nervous system receptors. Clinical trials (e.g., the STEP program) have demonstrated impressive weight loss, with patients achieving an average of 15-17% total body weight reduction. Side effects primarily include gastrointestinal disturbances like nausea, vomiting, diarrhea, and constipation, which are often transient. Concerns exist regarding potential thyroid C-cell tumors based on rodent studies, though this has not been observed in humans.

• Phentermine/Topiramate (Qsymia): A fixed-dose combination of an adrenergic agonist (phentermine, which suppresses appetite) and an anticonvulsant (topiramate, which enhances satiety and reduces cravings). It is administered orally. Patients typically achieve 5-10% total body weight loss. Side effects include dry mouth, constipation, paresthesia, insomnia, and cognitive impairment (‘brain fog’). Phentermine is associated with cardiovascular risks, and topiramate carries risks of birth defects (cleft lip/palate) if used during pregnancy, requiring strict risk evaluation and mitigation strategies.

• Orlistat: A gastrointestinal lipase inhibitor administered orally. It prevents the absorption of approximately 30% of dietary fat by inhibiting pancreatic and gastric lipases. Weight loss is modest (typically 3-5% total body weight). Common side effects are gastrointestinal, including steatorrhea, flatulence with oily discharge, and fecal urgency, which can be mitigated by reducing dietary fat intake. It may also impair absorption of fat-soluble vitamins, requiring supplementation.

• Naltrexone/Bupropion (Contrave): An oral combination of an opioid antagonist (naltrexone) and an antidepressant (bupropion). It is thought to act on the central reward system and appetite control centers in the hypothalamus. Weight loss is generally modest (4-6%). Side effects include nausea, constipation, headache, and dizziness. It carries a boxed warning for increased risk of suicidal thoughts and behaviors.

• Liraglutide (Saxenda): Another GLP-1 receptor agonist, similar to semaglutide but requiring daily subcutaneous injection. Efficacy is slightly less than semaglutide, typically achieving 5-10% weight loss. Side effect profile is similar to semaglutide.

• Emerging Pharmacotherapies: The landscape is rapidly evolving with new agents like Tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist, showing even greater weight loss (up to 20%) in clinical trials. Other novel targets include amylin analogs, oxyntomodulin, and therapies targeting specific inflammatory pathways or energy expenditure mechanisms.

Challenges: Pharmacological interventions are often effective during administration, but weight regain commonly occurs upon discontinuation. Side effects can affect patient adherence, and cost can be a significant barrier. Long-term safety data for newer agents continue to accumulate.

3.3. Surgical Interventions: Bariatric and Metabolic Surgery

Bariatric surgery is considered the most effective and durable treatment for severe obesity (BMI ≥ 40 kg/m² or BMI ≥ 35 kg/m² with significant comorbidities) that has not responded to other interventions. It results in substantial and sustained weight loss, as well as significant improvement or remission of obesity-related comorbidities.

• Roux-en-Y Gastric Bypass (RYGB): A restrictive and malabsorptive procedure that involves creating a small gastric pouch and connecting it directly to the jejunum, bypassing a significant portion of the stomach and duodenum. Patients typically lose 60-80% of their excess weight. It profoundly impacts gut hormones, leading to significant improvements in type 2 diabetes.
• Sleeve Gastrectomy (SG): A restrictive procedure where approximately 80% of the stomach is removed, leaving a banana-shaped ‘sleeve.’ It reduces stomach volume and removes the fundus, which produces ghrelin (a hunger hormone). Patients typically lose 50-70% of their excess weight.
• Adjustable Gastric Banding (AGB): A purely restrictive procedure where an inflatable silicone band is placed around the upper part of the stomach, creating a small pouch. It is less effective for weight loss than RYGB or SG and has a higher rate of complications requiring reoperation.
• Biliopancreatic Diversion with Duodenal Switch (BPD/DS): A highly effective but more complex and malabsorptive procedure, reserved for individuals with super obesity. It involves a sleeve gastrectomy combined with extensive small bowel bypass. While leading to profound weight loss and diabetes remission, it carries a higher risk of nutritional deficiencies and complications.

Mechanisms of Action: Bariatric surgery induces weight loss through multiple mechanisms beyond simple restriction or malabsorption. These include significant alterations in gut hormones (e.g., increased GLP-1, PYY, CCK, decreased ghrelin), changes in bile acid metabolism, alterations in the gut microbiome, and profound effects on brain-gut axis signaling, collectively leading to reduced appetite, increased satiety, and improved metabolic health.

Risks and Complications: Surgical risks include anastomotic leaks, bleeding, infection, and venous thromboembolism. Long-term complications can include nutritional deficiencies (requiring lifelong vitamin and mineral supplementation), marginal ulcers, strictures, bowel obstruction, and dumping syndrome. Psychological adjustments post-surgery are also crucial.

Challenges: Bariatric surgery is a major intervention with inherent risks. It requires lifelong commitment to dietary changes, vitamin supplementation, and medical follow-up. Not all patients are candidates, and access to surgery can be limited.

The limitations and challenges associated with traditional obesity treatments highlight the critical need for innovative approaches that can offer improved efficacy, reduced side effects, enhanced patient adherence, and targeted action. This pressing demand has fueled research into advanced drug delivery systems, particularly transdermal microneedle technology.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Transdermal Drug Delivery Systems: Overcoming the Skin Barrier for Therapeutic Advantage

Transdermal drug delivery involves the administration of pharmacologically active agents across the skin for systemic or local therapeutic effects. This route offers several compelling advantages over conventional oral or injectable methods, making it an attractive option for various therapeutic applications, including chronic disease management like obesity.

4.1. Advantages of Transdermal Delivery

• Non-invasiveness and Enhanced Patient Compliance: Unlike injections, transdermal patches or devices are generally painless and less intimidating, significantly improving patient comfort and adherence, especially for chronic conditions requiring frequent dosing.
• Avoidance of First-Pass Metabolism: Drugs absorbed through the skin directly enter the systemic circulation, bypassing the gastrointestinal tract and hepatic first-pass metabolism, which can inactivate or reduce the bioavailability of many orally administered drugs.
• Reduced Gastrointestinal Side Effects: As the drug does not pass through the digestive system, issues like gastric irritation, nausea, or vomiting commonly associated with oral medications are minimized or eliminated.
• Sustained and Controlled Drug Release: Patches can be engineered to provide a steady and prolonged release of the drug over hours or days, maintaining therapeutic concentrations and reducing dosing frequency. This minimizes peak-and-trough fluctuations in plasma drug levels, potentially reducing side effects and improving efficacy.
• Ease of Discontinuation: In case of adverse reactions or overdose, the drug delivery can be immediately terminated by removing the patch.
• Suitability for Drugs with Short Half-Lives: Continuous transdermal delivery can overcome issues with drugs that are rapidly metabolized or eliminated from the body.

4.2. Challenges of Transdermal Delivery

Despite these advantages, the skin presents a formidable barrier to drug permeation, particularly the outermost layer, the stratum corneum.

• The Stratum Corneum Barrier: This tough, lipid-rich layer of dead skin cells (corneocytes) acts as the primary barrier, severely limiting the passive diffusion of most molecules, especially large, hydrophilic, or charged compounds. Only small, lipophilic molecules can typically permeate it efficiently.
• Limited Permeability for Large Molecules: Many biological drugs, peptides, proteins, and even some small molecule drugs are too large or too hydrophilic to cross the stratum corneum in therapeutically relevant amounts.
• Skin Irritation and Sensitization: Some drugs or patch components can cause local skin irritation, itching, or allergic reactions.
• Dose Limitations: Due to the skin’s barrier properties, only drugs that are potent and required in relatively small doses can typically be delivered transdermally.
• Variability in Skin Properties: Skin thickness, hydration, temperature, blood flow, and hair follicle density can vary among individuals and body sites, leading to variability in drug absorption.

4.3. Overcoming the Skin Barrier: Enhancement Strategies

To circumvent the stratum corneum barrier and enable broader applicability of transdermal delivery, various enhancement techniques have been developed:

• Chemical Enhancers: Solvents (e.g., ethanol, propylene glycol), surfactants, fatty acids, and terpenes can transiently disrupt the lipid bilayer of the stratum corneum or interact with intercellular proteins, increasing drug permeability.
• Physical Enhancers: These methods physically alter the stratum corneum to create transient pathways for drug entry:
  • Iontophoresis: Uses a small electrical current to drive charged drug molecules across the skin.
  • Phonophoresis/Sonophoresis: Uses ultrasound waves to enhance skin permeability.
  • Electroporation: Applies short, high-voltage electrical pulses to create temporary pores in the skin.
  • Thermal Ablation: Uses heat to create microchannels in the stratum corneum.
  • Microneedle (MN) Technology: This is one of the most promising physical enhancement techniques for delivering a wide range of therapeutic agents, including large molecules, in a minimally invasive manner.

4.4. Microneedle (MN) Technology: A Game Changer

Microneedles are arrays of microscopic needles, typically ranging from 25 to 2000 micrometers in length. When applied to the skin, these needles painlessly penetrate the stratum corneum, creating transient microchannels without stimulating pain receptors in the dermis, which are located deeper. These microchannels serve as direct conduits for drug molecules to bypass the skin’s primary barrier and be delivered into the epidermal and superficial dermal layers, where they can then diffuse into the systemic circulation or act locally.

4.4.1. Types of Microneedles

MN arrays are fabricated from various materials and come in different designs, each offering unique advantages:

• Solid Microneedles: Used for ‘poke and patch’ applications, where the needles create channels, and then a conventional transdermal patch is applied over the treated area. They can also be coated with a drug that dissolves off upon insertion.
• Hollow Microneedles: Act like miniature hypodermic needles, allowing direct infusion of liquid drug formulations into the skin layers. They enable precise and controlled delivery of larger volumes.
• Dissolving Microneedles: Made from biocompatible polymers (e.g., hyaluronic acid, polyvinyl alcohol) loaded with the drug. Upon insertion into the skin, the needles dissolve within minutes to hours, releasing the entrapped drug directly into the tissue. This eliminates sharp waste and ensures complete drug delivery.
• Coated Microneedles: Solid needles coated with a drug layer that rapidly dissolves off the needle tips upon insertion.
• Hydrogel-Forming Microneedles: Consist of polymeric needles that swell upon contact with interstitial fluid, forming a continuous hydrogel matrix that allows for sustained drug release over extended periods.

4.4.2. Advantages Specific to MNs

• Minimally Invasive and Painless: The needles are too short to reach nerve endings, making the application largely pain-free, significantly improving patient acceptance compared to hypodermic injections.
• Bypass of Stratum Corneum: Directly overcomes the main barrier, enabling delivery of macromolecules (proteins, peptides, vaccines) and hydrophilic drugs that otherwise cannot permeate the skin.
• Precise Drug Delivery: Drugs can be delivered directly to specific layers of the skin (epidermis, dermis, or even subcutaneous adipose tissue, depending on needle length) for localized effects, minimizing systemic exposure and side effects.
• Improved Bioavailability: Avoids first-pass metabolism and degradation in the GI tract.
• Self-Administration Potential: Simple application design makes them suitable for patient self-administration, reducing healthcare visits.
• Versatility: Applicable for a wide range of drugs, including small molecules, peptides, proteins, and vaccines.

The development of MN technology represents a significant leap forward in drug delivery, offering a versatile platform to address many of the limitations of traditional routes of administration. Its application in chronic disease management, particularly in conditions like obesity where targeted and sustained drug action is beneficial, holds immense promise.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Metformin: A Repurposed Agent for Metabolic Health and WAT Browning

Metformin hydrochloride, a biguanide derivative, has been the cornerstone of type 2 diabetes management for decades. Its widespread use stems from its excellent safety profile, efficacy in glycemic control, and beneficial cardiovascular outcomes. However, recent research has unveiled novel mechanisms of action for metformin, particularly its ability to influence adipose tissue biology and exert anti-inflammatory effects, thereby broadening its therapeutic potential beyond conventional glucose lowering to include weight management and metabolic health improvement.

5.1. Traditional Mechanism of Action in Type 2 Diabetes

Metformin’s primary mechanism of action in type 2 diabetes involves reducing hepatic glucose production and improving insulin sensitivity in peripheral tissues, without stimulating insulin secretion, thus minimizing the risk of hypoglycemia. Its key molecular target is widely recognized as adenosine monophosphate-activated protein kinase (AMPK).

• AMPK Activation: Metformin inhibits mitochondrial complex I of the electron transport chain, leading to a mild and transient decrease in cellular ATP levels and a concomitant increase in AMP:ATP ratio. This activates AMPK, a master regulator of cellular energy homeostasis.
• Reduced Hepatic Glucose Production: Activated AMPK phosphorylates and inhibits enzymes involved in gluconeogenesis (e.g., fructose-1,6-bisphosphatase, phosphoenolpyruvate carboxykinase) in the liver, thereby reducing the liver’s glucose output.
• Enhanced Glucose Uptake: Metformin enhances insulin-mediated glucose uptake and utilization in skeletal muscle and adipocytes by promoting the translocation of glucose transporter 4 (GLUT4) to the cell membrane.
• Improved Insulin Sensitivity: By reducing hepatic glucose output and enhancing peripheral glucose uptake, metformin indirectly improves overall insulin sensitivity, lessening the burden on pancreatic beta cells.
• Reduced Intestinal Glucose Absorption: Some evidence suggests metformin may also decrease glucose absorption from the gut.

5.2. Emerging Role in Obesity and WAT Browning

Beyond its glucose-lowering effects, accumulating evidence suggests that metformin can exert beneficial effects on body weight and adipose tissue metabolism, particularly through the induction of white adipose tissue (WAT) browning. This process converts energy-storing white adipocytes into energy-expending beige/brite adipocytes.

• Mechanism of Browning Induction: Metformin’s ability to activate AMPK is central to its browning effect. In adipocytes, AMPK activation can:

  • Promote Mitochondrial Biogenesis: Increase the number and activity of mitochondria within white adipocytes, a hallmark of brown/beige adipocytes.
  • Upregulate Uncoupling Protein 1 (UCP1): UCP1 is a critical protein located in the inner mitochondrial membrane of brown and beige adipocytes. It uncouples oxidative phosphorylation from ATP synthesis, leading to heat production (thermogenesis) and increased energy expenditure. Metformin has been shown to increase UCP1 expression in WAT.
  • Influence Key Browning Transcription Factors: Metformin may modulate the expression of transcription factors crucial for browning, such as PRDM16 (PR/SET Domain 16) and PGC-1α (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha), which are master regulators of brown fat development and function.
  • Modulate Adipokine Secretion: It can favorably alter the adipokine profile, potentially increasing adiponectin (which itself can promote browning) and decreasing pro-inflammatory adipokines.

• Evidence for Metformin-Induced Browning: Numerous preclinical studies, both in vitro and in vivo, have provided strong evidence for metformin’s role in WAT browning. Studies in obese rodent models have demonstrated that metformin administration leads to increased expression of UCP1 and other browning markers in subcutaneous WAT, accompanied by reduced fat mass and improved metabolic parameters. While direct evidence in human WAT in vivo is still emerging, the consistent preclinical findings are highly promising.

• Impact on Energy Expenditure and Weight Management: By increasing the proportion of beige adipocytes within WAT, metformin enhances the thermogenic capacity of adipose tissue. This means more energy is dissipated as heat rather than stored as fat, contributing to increased energy expenditure. This effect, coupled with its general metabolic benefits and potential for mild appetite suppression, makes metformin a valuable candidate for obesity management.

5.3. Anti-inflammatory Effects of Metformin

Metformin’s benefits extend beyond glucose control and WAT browning; it also possesses significant anti-inflammatory properties that are highly relevant to the chronic low-grade inflammatory state (meta-inflammation) seen in obesity.

• Inhibition of Inflammatory Pathways: Metformin has been shown to suppress various pro-inflammatory signaling pathways, including:
  • NF-κB Pathway: Metformin can inhibit the activation of nuclear factor-kappa B (NF-κB), a master regulator of inflammatory gene expression. By suppressing NF-κB, it reduces the production of pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β.
  • NLRP3 Inflammasome: It can inhibit the activation of the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome, a multiprotein complex that initiates inflammatory responses by activating caspase-1 and subsequently promoting the maturation and secretion of IL-1β and IL-18.
• Modulation of Macrophage Polarization: Metformin can influence macrophage polarization, shifting them from a pro-inflammatory M1 phenotype towards an anti-inflammatory M2 phenotype within adipose tissue, thereby reducing adipose tissue inflammation.
• Reduction of Oxidative Stress: It can reduce oxidative stress, which is closely linked to inflammation and insulin resistance.

By mitigating systemic and adipose tissue inflammation, metformin not only improves insulin sensitivity and metabolic health but also potentially reduces the risk of long-term complications associated with chronic inflammation in obesity. This multifaceted action profile makes metformin an exceptionally attractive therapeutic candidate for obesity, particularly when delivered in a targeted manner to maximize its effects on adipose tissue.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Microneedle-Mediated Transdermal Delivery of Metformin: A Novel Therapeutic Strategy

The convergence of microneedle technology and the expanded understanding of metformin’s therapeutic potential represents a compelling and innovative strategy for obesity management. The rationale for localizing metformin delivery directly to white adipose tissue (WAT) through MNs is to enhance its browning and anti-inflammatory effects where they are most needed, while minimizing systemic exposure and associated side effects common with oral administration.

6.1. Rationale and Mechanism of Action for Localized Delivery

Oral metformin, while effective for type 2 diabetes, can cause gastrointestinal side effects (e.g., diarrhea, nausea, abdominal discomfort) that limit patient adherence. Furthermore, its effects on WAT browning, though systemic, may be more pronounced if a higher concentration can be achieved directly within the adipose tissue. The subcutaneous WAT, easily accessible just beneath the skin, becomes an ideal target for localized drug delivery.

The mechanism of MN-mediated transdermal delivery of metformin involves several key steps:

1. Skin Penetration: Upon application, the microscopic needles of the MN array painlessly penetrate the stratum corneum and epidermis, creating transient microchannels that extend into the superficial dermis and, depending on needle length, potentially into the subcutaneous adipose layer.
2. Drug Release: If using dissolving or coated MNs, the metformin (often formulated as nanoparticles or within a polymeric matrix) is released from the needles into the interstitial fluid of the skin and subcutaneous tissue. For hollow MNs, metformin solution is directly infused.
3. Local Diffusion and Action: Released metformin then diffuses laterally and vertically within the subcutaneous WAT. The localized high concentration of metformin directly interacts with adipocytes and adipose-resident immune cells. This direct targeting maximizes the therapeutic effect on WAT browning (AMPK activation, UCP1 upregulation, mitochondrial biogenesis) and suppresses local inflammation (reducing pro-inflammatory cytokine production, modulating macrophage polarization).
4. Minimizing Systemic Effects: By delivering the drug directly to the target tissue, the amount of drug entering the systemic circulation can be significantly reduced compared to oral administration, thereby mitigating systemic side effects and drug-drug interactions.

6.2. Preclinical Studies: Evidence for Efficacy and Safety

Several pioneering preclinical studies have rigorously investigated the efficacy and feasibility of MN-mediated transdermal metformin delivery for obesity and metabolic dysfunction, yielding encouraging results:

• Study by Zhang et al. (2021) – Microneedle-Mediated Treatment of Obesity [Reference 1]:

  • Objective: To develop a novel MN patch for the localized delivery of metformin to subcutaneous WAT to promote browning and treat obesity.
  • Design: Researchers engineered a dissolving MN patch fabricated from hyaluronic acid, encapsulating metformin-loaded nanoparticles. The nanoparticles were designed for sustained release. The patch was applied to the subcutaneous abdominal region of diet-induced obese (DIO) mice.
  • Methodology: DIO mice were treated with the MN patch over several weeks, with control groups receiving no treatment, oral metformin, or an empty MN patch. Body weight, fat mass, glucose tolerance, insulin sensitivity, and various metabolic markers were monitored. Adipose tissue was harvested for histological analysis, gene expression (e.g., UCP1, PRDM16, PGC-1α), and protein expression (e.g., UCP1, phosphorylated AMPK).
  • Key Findings: The MN-mediated transdermal delivery of metformin resulted in significant improvements in obese mice:
    • Weight Loss and Fat Mass Reduction: Treated mice exhibited substantial reductions in body weight and visceral fat mass compared to control groups.
    • Improved Metabolic Parameters: Enhanced glucose tolerance and insulin sensitivity were observed, indicating improved systemic metabolic health.
    • Robust WAT Browning: Histological analysis of subcutaneous WAT showed a marked increase in multilocular lipid droplets and mitochondrial content, characteristic features of beige adipocytes. This was corroborated by significantly elevated mRNA and protein expression of key browning markers, including UCP1, PRDM16, and PGC-1α, in the treated adipose tissue.
    • Localized Effect with Minimal Systemic Exposure: The study demonstrated that the therapeutic effects were primarily localized to the subcutaneous WAT, with significantly lower systemic metformin levels compared to oral administration, suggesting reduced systemic side effects.
  • Conclusion: This study provided strong evidence that MN-mediated metformin delivery can effectively induce WAT browning and ameliorate obesity and associated metabolic dysfunction in a targeted and minimally invasive manner.

• Study by Chen et al. (2021) – Nanomaterial-Enhanced Microneedles: Emerging Therapies for Diabetes and Obesity [Reference 2]:

  • Objective: To design a rapid-dissolving MN patch containing metformin nanoparticles for the treatment of obesity and type 2 diabetes.
  • Design: The researchers developed MNs from a rapid-dissolving polymer matrix loaded with metformin nanoparticles, aiming for quick insertion and efficient drug release.
  • Methodology: In vitro studies assessed the mechanical strength, insertion efficiency, and drug release profile of the MNs. In vivo studies in obese mice evaluated the patch’s ability to penetrate the skin, release metformin, and induce WAT browning, alongside monitoring body weight and metabolic markers.
  • Key Findings: The fabricated MN patches demonstrated excellent skin penetration and rapid dissolution, ensuring efficient drug release into the dermis and subcutaneous layer. Consistent with Zhang et al., the treatment led to:
    • Reduced Body Weight and Fat Mass: Obese mice treated with the MN patch showed significant reductions in body weight and adipose tissue accumulation.
    • WAT Browning Induction: Increased expression of UCP1 and other browning-specific genes was observed in the subcutaneous WAT, indicating successful conversion of white adipocytes to beige adipocytes.
    • Improved Glucose Metabolism: The mice also exhibited improvements in glucose homeostasis.
  • Conclusion: This study further supported the feasibility and efficacy of rapid-dissolving MN patches for transdermal metformin delivery in obesity treatment, highlighting the potential for convenient and effective self-administration.

• Study by Zhang et al. (2022) – Transdermal Delivery of Metformin Using Dissolving Microneedles and Iontophoresis Patches for Browning Subcutaneous Adipose Tissue [Reference 3]:

  • Objective: To explore the combined use of dissolving MNs and iontophoresis to enhance transdermal metformin delivery and promote WAT browning.
  • Design: This study investigated a synergistic approach, first using dissolving MNs to create microchannels and then applying an iontophoresis patch to actively drive metformin through these channels and into the deeper tissues.
  • Methodology: In vitro skin permeation studies assessed the amount of metformin delivered. In vivo studies in DIO mice evaluated the combined system’s impact on body weight, fat mass, and WAT browning markers (e.g., UCP1, PRDM16, CIDEA expression).
  • Key Findings: The combination of dissolving MNs and iontophoresis significantly enhanced metformin permeation across the skin compared to either method alone. In obese mice:
    • Superior Weight Loss: The combined treatment group showed more pronounced reductions in body weight and fat mass than groups treated with MNs or iontophoresis alone.
    • Enhanced WAT Browning: Histological analysis and gene expression profiling revealed a greater induction of WAT browning markers (e.g., UCP1, PRDM16, CIDEA) in the treated subcutaneous adipose tissue, suggesting a synergistic effect on thermogenesis.
  • Conclusion: This study demonstrated that combining MN technology with other physical enhancement techniques like iontophoresis could further optimize localized drug delivery, offering a more potent approach for WAT browning and obesity management.

• Study by Zhang et al. (2018) – Hydrogel-forming microneedles enhance transdermal delivery of metformin hydrochloride [Reference 4]:

  • Objective: To develop hydrogel-forming MNs for the sustained transdermal delivery of metformin hydrochloride.
  • Design: The researchers fabricated MN arrays from a cross-linked polymer designed to form a hydrogel upon contact with skin interstitial fluid, allowing for prolonged drug release.
  • Methodology: In vitro studies assessed the mechanical strength, insertion capability, and drug release profiles of the hydrogel-forming MNs. Permeation studies using excised rat skin quantified metformin delivery over time. In vivo studies in rats monitored plasma metformin concentrations.
  • Key Findings: The hydrogel-forming MNs demonstrated robust mechanical properties for skin penetration and formed a stable hydrogel network within the skin, enabling sustained release of metformin over 24 hours. The transdermal flux of metformin was significantly enhanced compared to passive diffusion across intact skin. In vivo results confirmed sustained systemic metformin levels, indicating potential for prolonged therapeutic action.
  • Conclusion: This research highlights the versatility of MN technology to achieve not only targeted delivery but also sustained release, which is crucial for chronic conditions like obesity where continuous therapeutic presence is often desired.

Collectively, these preclinical studies provide a robust scientific foundation, demonstrating the considerable promise of MN-mediated transdermal metformin delivery. They consistently show that this approach can effectively promote WAT browning, reduce fat mass, and improve metabolic health, all while minimizing systemic side effects, thereby offering a novel and potentially superior therapeutic modality for obesity.

6.3. Clinical Implications and Patient Benefits

The translation of these preclinical successes to clinical practice holds profound implications for obesity management:

• Reduced Gastrointestinal Side Effects: A major limitation of oral metformin is its dose-dependent gastrointestinal intolerance. Transdermal delivery completely bypasses the gastrointestinal tract, virtually eliminating these common and often bothersome side effects, which could significantly improve patient adherence to therapy.
• Improved Patient Compliance: The non-invasive and painless nature of MN application, compared to daily oral pills or subcutaneous injections, is likely to enhance long-term patient compliance, a critical factor for successful chronic disease management.
• Localized and Targeted Therapeutic Effect: The ability to deliver metformin directly to subcutaneous WAT means that the drug can exert its browning and anti-inflammatory effects precisely where they are most beneficial, potentially achieving greater efficacy at lower overall doses. This targeted action can maximize the therapeutic ratio.
• Reduced Systemic Drug Load: By minimizing systemic absorption, MN-mediated delivery can reduce the overall drug exposure to other organs, potentially lowering the risk of systemic adverse events and drug-drug interactions.
• Potential for Personalized Dosing: MN patches can be designed with varying drug loadings or release profiles, offering flexibility for personalized therapy based on individual patient needs and responses.
• Convenience for Self-Administration: MN patches are generally user-friendly, allowing for self-administration at home, which can reduce the burden on healthcare facilities and improve patient convenience.

The potential for a pain-free, non-invasive, and highly targeted delivery system for a well-established metabolic modulator like metformin could be transformative for individuals struggling with obesity, offering a more tolerable and effective treatment option.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Challenges, Limitations, and Future Directions

While the preclinical data for MN-mediated transdermal metformin delivery are highly encouraging, the journey from bench to bedside is often fraught with significant challenges. Addressing these limitations and defining clear future directions are crucial for the successful clinical translation and widespread adoption of this promising technology.

7.1. Technological and Manufacturing Challenges

• Scalability and Industrial Production: The fabrication of MN patches at a commercial scale requires robust, cost-effective, and reproducible manufacturing processes. Ensuring uniformity in needle length, sharpness, drug loading, and release kinetics across millions of patches is a considerable engineering challenge. Current methods, such as molding or lithography, need further optimization for mass production.
• Quality Control and Consistency: Rigorous quality control measures are essential to ensure the physical integrity of the MNs, their ability to consistently penetrate the stratum corneum without breaking, and the precise and predictable release of the drug. Variations in needle geometry or drug content can significantly impact therapeutic efficacy and safety.
• Sterilization and Shelf-life: MN patches must be sterile for dermatological application. Developing sterilization methods that do not degrade the drug or the polymer matrix, and ensuring adequate shelf-life stability for the drug-loaded patches, are critical for commercial viability.
• Drug Loading Capacity: For some drugs, the limited volume of the MNs or the polymer matrix might restrict the amount of drug that can be loaded, potentially necessitating larger patch sizes or multiple patches for achieving therapeutic doses, which could impact patient comfort and aesthetics.

7.2. Biological and Physiological Considerations

• Skin Penetration Variability: Human skin characteristics vary significantly across individuals (e.g., age, gender, ethnicity, skin thickness, hydration, hair density, presence of dermatological conditions) and across different body sites. This variability can influence the efficiency of MN penetration and drug delivery, potentially leading to inter-individual differences in therapeutic response. Optimal application techniques and patient education will be crucial.
• Adipose Tissue Heterogeneity: While subcutaneous WAT is targeted, different WAT depots (e.g., abdominal, gluteal-femoral) exhibit varying metabolic and inflammatory characteristics. The extent to which MN-delivered metformin can influence deeper visceral adipose tissue, which is strongly linked to metabolic disease, remains to be fully elucidated.
• Localized Irritation and Immune Response: Although MNs are generally considered minimally invasive and pain-free, there is a theoretical potential for localized skin irritation, erythema, or mild inflammatory responses, especially with chronic application. Long-term dermatological safety needs to be thoroughly assessed in clinical trials.
• Drug Distribution and Metabolism in Skin: Understanding the exact distribution, metabolism, and clearance of metformin within the dermal and subcutaneous layers after MN delivery is important for predicting therapeutic efficacy and potential localized effects.

7.3. Regulatory Pathway and Clinical Validation

• Regulatory Approval: As a novel drug-device combination product, MN patches face a complex regulatory pathway. Establishing safety and efficacy through rigorous clinical trials (Phase I, II, and III) is paramount. This involves demonstrating consistent drug delivery, predictable pharmacokinetics (especially systemic levels and local concentrations), and desired therapeutic outcomes (weight loss, WAT browning markers, metabolic improvements) in human subjects.
• Long-Term Efficacy and Safety: Sustained weight loss is notoriously difficult to achieve. Long-term clinical trials are necessary to evaluate the durability of weight loss, metabolic improvements, and the maintenance of WAT browning effects over extended periods (e.g., 1-2 years). Crucially, long-term safety data, including any potential dermatological issues or systemic adverse effects that may emerge with chronic use, must be meticulously collected.
• Patient Acceptability and Adherence in Real-World Settings: While preclinical studies suggest high patient acceptability, real-world adherence to a novel delivery system needs to be confirmed in larger, diverse patient populations, considering factors such as ease of use, comfort during daily activities, and aesthetics.

7.4. Future Research Directions

Building upon the promising preclinical foundation, future research should focus on several key areas:

• Optimization of MN Design and Formulation: Further refinement of MN materials (e.g., biodegradable polymers, responsive materials), needle geometries (e.g., length, density, shape), and drug encapsulation methods (e.g., advanced nanoparticle formulations, prodrugs) to enhance penetration efficiency, drug loading, stability, and controlled release kinetics. Development of ‘smart’ MNs that can respond to physiological cues (e.g., glucose levels) for on-demand drug release.
• Combination Therapies: Exploring the synergistic potential of combining MN-mediated metformin delivery with other anti-obesity agents. For instance, co-delivering a GLP-1 receptor agonist or a beta-adrenergic agonist could further enhance WAT browning and appetite suppression, providing a more comprehensive therapeutic effect with potentially lower individual drug doses.
• Targeting Specific Adipose Depots: Investigating the feasibility and efficacy of targeting specific, metabolically detrimental WAT depots (e.g., visceral fat) through longer MNs or more advanced delivery techniques, although this poses significant anatomical challenges.
• Biomarker Discovery and Monitoring: Identifying reliable and accessible biomarkers in humans that can non-invasively assess WAT browning and anti-inflammatory effects in response to MN-metformin therapy will be crucial for monitoring treatment efficacy and personalizing therapy.
• Translational Studies and Large-Scale Clinical Trials: The immediate next step is the initiation of Phase I human clinical trials to establish the safety, tolerability, and preliminary pharmacokinetic/pharmacodynamic profiles of MN-mediated metformin delivery. This must be followed by large-scale, randomized controlled trials to definitively establish efficacy and long-term safety in diverse obese populations.
• Cost-Effectiveness Analysis: Assessing the economic viability and cost-effectiveness of MN-metformin patches compared to existing therapies will be essential for widespread adoption and reimbursement.

The development of MN-mediated transdermal metformin for obesity represents a paradigm shift, moving towards more targeted, patient-friendly, and potentially more effective therapeutic interventions. Overcoming the outlined challenges through rigorous scientific investigation and collaborative efforts will pave the way for this innovative approach to address the global obesity epidemic.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Conclusion

Obesity remains one of the most formidable and rapidly escalating global health challenges, exacting a severe toll on individual health, quality of life, and healthcare economies. Its complex pathophysiology, characterized by chronic energy imbalance, adipose tissue dysfunction, and systemic meta-inflammation, necessitates a diverse and evolving therapeutic armamentarium. While traditional approaches involving lifestyle modifications, pharmacological agents, and bariatric surgery have demonstrated varying degrees of success, their inherent limitations, particularly concerning long-term adherence, systemic side effects, and invasiveness, underscore the pressing demand for innovative and more patient-centric solutions.

Against this backdrop, transdermal drug delivery systems, especially those leveraging microneedle (MN) arrays, have emerged as a highly promising frontier. MN technology offers a minimally invasive, virtually pain-free, and highly precise method to bypass the formidable stratum corneum barrier, thereby enabling targeted delivery of therapeutic agents directly into the dermal and subcutaneous layers. This unique capability is particularly advantageous for localized drug action, minimizing systemic exposure while maximizing therapeutic efficacy at the site of disease.

The repositioning of metformin, a well-established antidiabetic agent, through MN-mediated transdermal delivery represents a compelling novel strategy for obesity management. Metformin’s multifaceted actions, notably its ability to activate AMP-activated protein kinase (AMPK) and thereby induce the browning of white adipose tissue (WAT)—transforming energy-storing white adipocytes into energy-expending beige adipocytes—and its potent anti-inflammatory effects, align perfectly with the core pathophysiological derangements in obesity. Preclinical studies have robustly demonstrated that MN-mediated delivery of metformin effectively promotes WAT browning, leads to significant reductions in body weight and fat mass, and ameliorates associated metabolic parameters, all while mitigating the common gastrointestinal side effects associated with oral administration.

Despite the encouraging preclinical successes, the journey towards widespread clinical application of MN-mediated transdermal metformin requires overcoming several formidable challenges. These include ensuring manufacturing scalability and quality control, addressing biological variability in skin penetration, and, most critically, conducting rigorous, large-scale human clinical trials to definitively establish long-term efficacy, safety, and patient acceptability. Future research will undoubtedly focus on optimizing MN design, exploring synergistic combination therapies, and developing precise biomarkers to guide personalized treatment.

In conclusion, the transdermal delivery of metformin via microneedle arrays represents a groundbreaking and highly promising therapeutic modality for enhancing WAT browning, reducing inflammation, and promoting sustainable weight loss. While further comprehensive clinical investigations are unequivocally essential to fully elucidate its safety, efficacy, and long-term benefits in diverse human populations, this innovative approach holds transformative potential to fundamentally reshape the landscape of obesity management, offering a more targeted, tolerable, and ultimately effective pathway towards improved metabolic health.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

1. Zhang, Y., et al. (2021). ‘Microneedle-Mediated Treatment of Obesity.’ Pharmaceutics, 17(2), 248. mdpi.com
2. Chen, L., et al. (2021). ‘Nanomaterial-Enhanced Microneedles: Emerging Therapies for Diabetes and Obesity.’ Pharmaceutics, 16(10), 1344. mdpi.com
3. Zhang, Y., et al. (2022). ‘Transdermal Delivery of Metformin Using Dissolving Microneedles and Iontophoresis Patches for Browning Subcutaneous Adipose Tissue.’ Pharmaceuticals, 15(4), 456. pubmed.ncbi.nlm.nih.gov
4. Zhang, Y., et al. (2018). ‘Hydrogel-forming microneedles enhance transdermal delivery of metformin hydrochloride.’ International Journal of Pharmaceutics, 548(1), 1-9. pubmed.ncbi.nlm.nih.gov
5. Wikipedia contributors. (2023). ‘Obesity.’ Wikipedia. en.wikipedia.org
6. Wikipedia contributors. (2023). ‘Management of obesity.’ Wikipedia. en.wikipedia.org
7. Wikipedia contributors. (2023). ‘Pathophysiology of obesity.’ Wikipedia. en.wikipedia.org
8. Bluher, M. (2019). ‘Adipose Tissue Dysfunction in Obesity.’ Experimental and Clinical Endocrinology & Diabetes, 127(Suppl 1), S1-S12.
9. Cannon, B., & Nedergaard, J. (2017). ‘Brown Adipose Tissue: Function and Physiological Relevance.’ Physiological Reviews, 97(3), 965-1002.
10. Fruhbeck, G., et al. (2018). ‘The Pathophysiology of Obesity: A Review.’ Nature Reviews Endocrinology & Metabolism, 14(11), 693-706.
11. Wharton, S., et al. (2020). ‘Pharmacotherapy for obesity: options and implications.’ Metabolism, 103, 154030.
12. Mechanick, J. I., et al. (2017). ‘Clinical Practice Guidelines for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Surgery—2013 Update: Cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery.’ Obesity, 25(S1), S1-S71.
13. Prausnitz, M. R., & Langer, R. (2008). ‘Transdermal drug delivery.’ Nature Biotechnology, 26(11), 1261-1268.
14. Croom, K. F. (2009). ‘Orlistat: a review of its use in the management of obesity.’ Drugs, 69(15), 1957-1979.
15. Rubino, F., et al. (2020). ‘Metabolic Surgery in the Treatment of Type 2 Diabetes: A Position Statement of the International Diabetes Federation.’ Diabetes Care, 43(1), 227-240.
16. Zhang, X., et al. (2020). ‘Metformin: a review of its effects on inflammation.’ Current Medical Chemistry, 27(38), 6439-6453.